Skip to main content

Table 1 Inclusion criteria

From: FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial

Age: 19–70 years
Screening visit (Visit 1)
 Hypertension in treatment-naïve patients
  140 mmHg ≤ SBP < 180 mmHg and DBP < 110 mmHg
 Hypertension with treatment, including ACEI/ARB
  130 mmHg ≤ SBP < 180 mmHg and DBP < 110 mmHg
 eGFR ≥ 30 mL/min/1.73 m2 (by MDRD) within the past six months
 Urine protein (within the past six months)
  ACR ≥ 300 mg/g (or mg/day)
  or protein–creatinine ratio ≥ 500 mg/g (or mg/day)
 Type 2 diabetes mellitus (diagnosed > 3 months prior) on medications with
  no changes in medication regimen/dose within the last three months
Baseline visit (Visit 3)
 Hypertension
  140 mmHg ≤ SBP < 180 mmHg and DBP < 110 mmHg
 eGFR ≥ 30 mL/min/1.73 m2 (by MDRD)
 Urine protein: ACR ≥ 300 mg/g in spot urine
 Type 2 diabetes without regimen change during placebo run-in period
  1. SBP systolic blood pressure, DBP diastolic blood pressure, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, ACR albumin–creatinine ratio, eGFR estimated glomerular filtration rate, MDRD Modification of Diet in Renal Disease